Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 9 Stomach Neoplasms 2 Colonic Neoplasms 2 Thrombocytopenia 1 Squamous Cell Carcinoma of Head and Neck 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Liver, Cancer of, Primary Resectable 1 Inoperable Esophageal Cancer Stage I-III 1 Hepatocellular Carcinoma Resectable 1 Head and Neck Squamous Cell Cancer 1 Fruquintinib 1 Esophageal Squamous Cell Carcinoma 1 Colorectal Cancer Metastatic 1 Colon Cancer Liver Metastasis 1 Carcinoma, Hepatocellular 1 Advanced Metastatic Colorectal Cancer 1 Advanced Gastric Cancer 1 Advanced Colorectal Carcinoma 1 Advanced Colorectal Cancer 1

Interventions

Oxaliplatin 5 Irinotecan 5 Panitumumab 4 Capecitabine 4 Bevacizumab 4 Cetuximab 3 Leucovorin 2 Fluorouracil 2 trifluridine tipiracil drug combination 1 spartalizumab 1 regorafenib 1 raltitrexed 1 pembrolizumab 1 camrelizumab 1 aflibercept 1 XELOX 1 Radiotherapy 1 Radiosurgery 1 Lycopene 1 Loperamide 1 Ethiodized Oil 1 Drug Therapy 1 Cytoreduction Surgical Procedures 1 Antineoplastic Agents 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Colorectal Cancer Metastatic × raltitrexed × Clear all

NCT01959061 2017-03-13

TACE

Nanjing Chia-tai Tianqing Pharmaceutical

Phase 4 Unknown

Gastrointestinal

Colorectal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡